GNPX

Genprex, Inc.

2.20 USD
-0.03 (-1.35%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Genprex, Inc. stock is down -0.45% since 30 days ago. The next earnings date is Aug 19, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 28.57% of the previous 6 May’s closed higher than April. 100% of analysts rate it a buy.

About Genprex, Inc.

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes.

  • HC Wainwright & Co.
    Fri May 17, 08:16
    buy
    confirm
  • HC Wainwright & Co.
    Wed May 15, 11:26
    buy
    confirm